West Pharmaceutical Services Dividends and Buybacks
Dividend criteria checks 0/6
West Pharmaceutical Services is a dividend paying company with a current yield of 0.36%. Next payment date is on 6th May, 2026 with an ex-dividend date of 29th April, 2026.
Key information
0.4%
Dividend yield
0.7%
Buyback Yield
| Total Shareholder Yield | 1.0% |
| Future Dividend Yield | 0.4% |
| Dividend Growth | 6.3% |
| Next dividend pay date | 06 May 26 |
| Ex dividend date | 29 Apr 26 |
| Dividend per share | n/a |
| Payout ratio | 12% |
Recent dividend and buyback updates
Recent updates
West Pharmaceutical: Back To Growth
Dec 01West Pharmaceutical Services, Inc.'s (NYSE:WST) Shares Climb 25% But Its Business Is Yet to Catch Up
Jul 25
Here's Why West Pharmaceutical Services (NYSE:WST) Can Manage Its Debt Responsibly
Jul 13Calculating The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
May 19It Looks Like West Pharmaceutical Services, Inc.'s (NYSE:WST) CEO May Expect Their Salary To Be Put Under The Microscope
Apr 30West Pharmaceutical: Remains A Strong Long-Term Prospect
Mar 11West Pharmaceuticals Takes A Plunge, But May Still Offer Opportunities
Feb 17West Pharmaceuticals: Cannot Wrap My Head Around Valuations (Rating Downgrade)
Jan 08West Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes Sense
Oct 11West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
Jul 25Upcoming Dividend Payment
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: WST is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: WST is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Dividend Yield vs Market
| West Pharmaceutical Services Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (WST) | 0.4% |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Life Sciences) | 0.6% |
| Analyst forecast (WST) (up to 3 years) | 0.4% |
Notable Dividend: WST's dividend (0.36%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.47%).
High Dividend: WST's dividend (0.36%) is low compared to the top 25% of dividend payers in the US market (4.37%).
Earnings Payout to Shareholders
Earnings Coverage: WST is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: WST is not paying a notable dividend for the US market.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/24 19:46 |
| End of Day Share Price | 2026/03/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
West Pharmaceutical Services, Inc. is covered by 25 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lawrence Marsh | Barclays |
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |